Checkpoint Therapeutics, Inc. (CKPT)

Compare

3.9800

+0.0300

+(0.76%)

As of 2:03:18 PM EDT. Market Open.

High Growth Tech Stocks in the US for April 2025

Over the last 7 days, the United States market has dropped 5.6%, yet it remains up by 3.3% over the past year, with earnings projected to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves focusing on companies that can capitalize on robust earnings potential and demonstrate resilience amid recent market fluctuations.

Simply Wall St. 5 days ago

RDVT

CKPT
+0.76%
RIGL
3 Growth Companies Insiders Are Betting On

In the wake of recent market turbulence sparked by new tariffs, U.S. indices have experienced significant declines, highlighting the volatility and uncertainty that currently characterize the investment landscape. Amidst this backdrop, companies with high insider ownership can offer a unique perspective on potential growth opportunities, as insiders often have a deep understanding of their company's prospects and may be more inclined to invest in times of market stress.

Simply Wall St. 5 days ago

HSAI

CKPT
+0.76%
API
Checkpoint Therapeutics Full Year 2024 Earnings: US$1.42 loss per share (vs US$1.87 loss in FY 2023)

Checkpoint Therapeutics ( NASDAQ:CKPT ) Full Year 2024 Results Key Financial Results Net loss: US$56.2m (loss widened...

Simply Wall St. 11 days ago

CKPT
+0.76%
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the fiscal year ended December 31, 2024, and recent corporate updates. Recent Corporate Updates: In March 2025, Checkpoint announced that it entered in

GlobeNewswire 12 days ago

FBIO
+4.89%
FBIOP

CKPT
+0.76%
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shift From Loss To Profit

We feel now is a pretty good time to analyse Checkpoint Therapeutics, Inc.'s ( NASDAQ:CKPT ) business as it appears the...

Simply Wall St. 24 days ago

CKPT
+0.76%
Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index shedding 1.4% a

PREMIUM
MT Newswires 29 days ago

CKPT
+0.76%
MLYS

PTGX
Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday

(Adds Checkpoint's stock move in the headline and first paragraph. Adds Fortress Biotech's stock mov

PREMIUM
MT Newswires 30 days ago

CKPT
+0.76%
SUNPHARMA.NS

FBIO
+4.89%
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details

On Sunday, India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) for an upfront cash payment of $4.10/share. In December, the FDA approved Checkpoint Therapeutics’ Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Unloxcyt is the first and only programmed death

Benzinga 30 days ago

CKPT
+0.76%
SUNPHARMA.NS
Sun Pharma agrees to acquire Checkpoint Therapeutics

Stockholders of Checkpoint are set to obtain an upfront cash payment of $4.10 per share of common stock.

Pharmaceutical Technology 30 days ago

CKPT
+0.76%
SUNPHARMA.NS
India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million.

Investing.com 30 days ago

CKPT
+0.76%
SUNPHARMA.NS
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations. Last year, it signed a licensing agreement with Italian-Swiss firm Philogen for its anti-cancer drug Fibromun. Monday's transaction, which is expected to be completed in the second quarter of 2025, will add UNLOXCYT, a U.S. FDA-approved treatment for advanced skin cancer, to Sun Pharma's global franchise.

Reuters 30 days ago

CKPT
+0.76%
SUNPHARMA.NS
Sun Pharma to Acquire Checkpoint Therapeutics

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company.

PR Newswire 30 days ago

FBIO
+4.89%
FBIOP

CKPT
+0.76%
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) stock most popular amongst individual investors who own 56%, while public companies hold 14%

Key Insights The considerable ownership by individual investors in Checkpoint Therapeutics indicates that they...

Simply Wall St. 2 months ago

CKPT
+0.76%
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Unloxcyt is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. The recommended commercial dosage of Unloxcyt is 1,200 mg administered as an intravenous infusion over 60 minute

Benzinga 3 months ago

CKPT
+0.76%
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or curative r

GlobeNewswire 3 months ago

FBIO
+4.89%
FBIOP

CKPT
+0.76%
Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)

Checkpoint Therapeutics ( NASDAQ:CKPT ) Third Quarter 2024 Results Key Financial Results Net loss: US$9.73m (loss...

Simply Wall St. 4 months ago

CKPT
+0.76%
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates. “With the Prescription Drug User Fee Act (“PDUFA”) goal date set for next month, we await the decision by t

GlobeNewswire 4 months ago

FBIO
+4.89%
FBIOP

CKPT
+0.76%
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”)

GlobeNewswire 6 months ago

CKPT
+0.76%
FBIO
+4.89%
FBIOP
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference. A webcas

GlobeNewswire 7 months ago

CKPT
+0.76%
FBIO
+4.89%
FBIOP
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock

Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 7 months ago

CKPT
+0.76%

Performance Overview

Return	CKPT	S&P 500 (^GSPC)
YTD	+24.37%	-8.40%
1-Year	+117.49%	+3.40%
3-Year	-74.65%	+20.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Checkpoint Therapeutics, Inc. (CKPT)

High Growth Tech Stocks in the US for April 2025

3 Growth Companies Insiders Are Betting On

Checkpoint Therapeutics Full Year 2024 Earnings: US$1.42 loss per share (vs US$1.87 loss in FY 2023)

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shift From Loss To Profit

Sector Update: Health Care Stocks Decline Late Afternoon

Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday

India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details

Sun Pharma agrees to acquire Checkpoint Therapeutics

India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million

Sun Pharma to Acquire Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) stock most popular amongst individual investors who own 56%, while public companies hold 14%

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock

Performance Overview